Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?
This article was originally published in The Pink Sheet
Executive Summary
Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.